Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Nayak, Smita ^a   Roberts, Mark S ^a,b   Greenspan, Susan L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; GENERIC DRUG;

AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAGILITY FRACTURE; HOSPITAL ADMISSION; HUMAN; MONTE CARLO METHOD; NURSING HOME; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; METHODOLOGY; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; STATISTICAL MODEL; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; AGED; ALENDRONATE; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; FEMALE; HUMANS; MASS SCREENING; MODELS, ECONOMIC; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 84858116894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032879     Document Type: Article

References (53)

1. National Osteoporosis Foundation (2005) About Osteoporosis: Fast Facts Washington, DC National Osteoporosis Foundation.
2. Nelson HD, Helfand M, Woolf SH, Allan JD, (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137: 529-541.
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, et al. (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22: 465-475.
4. US Department of Health and Human Service, Office of the Surgeon General (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD.
5. US Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154 (5): 356-64.
6. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, et al. (2006) The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166: 1209-1217.
7. Tosteson AN, Burge RT, Marshall DA, Lindsay R, (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14: 605-615.
8. Schousboe JT, (2007) Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep 9: 50-56.
9. Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL, (2005) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 53: 1697-1704.
10. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK, (2006) Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 26: 194-206.
11. Fleurence RL, Iglesias CP, Johnson JM, (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics 25: 913-933.
12. The (2010) Drug Topics Red Book.: Physician's Desk Reference.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
14. Nayak S, Roberts MS, Greenspan SL, (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155 (11): 751-61.
15. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, et al. (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8: 468-489.
16. Lu Y, Genant HK, Shepherd J, Zhao S, Mathur A, et al. (2001) Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 16: 901-910.
17. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
18. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, et al. (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 25 (5): 976-982.
19. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, et al. (2005) Compliance with osteoporosis medications. Arch Intern Med 165: 2414-2419.
20. Recker RR, Gallagher R, MacCosbe PE, (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80: 856-861.
21. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, et al. (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332: 767-773.
22. Melton LJ 3rd, Lane AW, Cooper C, Eastell R, O'Fallon WM, et al. (1993) Prevalence and incidence of vertebral deformities. Osteoporos Int 3: 113-119.
23. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 1437-1443.
24. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, et al. (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277: 1159-1164.
25. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082.
26. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 4118-4124.
27. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535-1541.
28. Tosteson AN, Jonsson B, Grima DT, O'Brien BJ, Black DM, et al. (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12: 849-857.
29. Arias E, (2007) United states life tables, 2004. Natl Vital Stat Rep 56: 1-39.
30. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, et al. (2004) Mortality after osteoporotic fractures. Osteoporos Int 15: 38-42.
31. US Congress, Office of Technology Assessment (1994) Hip Fracture Outcomes in People Age 50 and Over- Background Paper. OTA-BP-H-120 Washington, DC U.S. Government Printing Office.
32. Corliss GR, Lucas R, Newton M, Tillman K, (2004) Long-Term Care Experience Committee Intercompany Study 1984-2001. Society of Actuaries.
33. Braithwaite RS, Col NF, Wong JB, (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51: 364-370.
34. Fitzgerald JF, Moore PS, Dittus RS, (1988) The care of elderly patients with hip fracture. Changes since implementation of the prospective payment system. N Engl J Med 319: 1392-1397.
35. Centers for Medicare and Medicaid Services national physician fee schedule website. Available: http://www.cms.hhs.gov/PFSlookup/. Accessed 2010 Dec 16.
36. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, et al. (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13: 323-330.
37. THE (2003) GE Financial Nursing Home Cost of Care Survey Richmond, VA GE Financial Assurance Holdings Inc.
38. The (2010) U.S. Consumer Price Index for Medical Care for All Urban Consumers U.S. Department of Labor Bureau of Labor Statistics.
39. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG, (2006) Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 26: 391-400.
40. Brazier JE, Green C, Kanis JA, (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13: 768-776.
41. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, et al. (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15: 1384-1392.
42. Dolan P, Torgerson D, Kakarlapudi TK, (1999) Health-related quality of life of Colles' fracture patients. Osteoporos Int 9: 196-199.
43. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, et al. (1993) The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 13: 89-102.
44. Brazier J, Kohler B, Walters S, (2000) A prospective study of the health related quality of life impact of hip fractures University of Sheffield.
45. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, et al. (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15: 20-26.
46. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, et al. (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12: 1042-1049.
47. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, et al. (2009) Deaths: final data for 2006. Natl Vital Stat Rep 57: 1-134.
48. Cummings SR, Black DM, Rubin SM, (1989) Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149: 2445-2448.
49. Barrett JA, Baron JA, Karagas MR, Beach ML, (1999) Fracture risk in the U.S. Medicare population. J Clin Epidemiol 52: 243-249.
50. Russell LB, (2009) Preventing chronic disease: an important investment, but don't count on cost savings. Health Aff (Millwood) 28: 42-45.
51. Woolf SH, (2009) A closer look at the economic argument for disease prevention. JAMA 301: 536-538.
52. Schousboe JT, Nyman JA, Kane RL, Ensrud KE, (2005) Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142: 734-741.
53. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, et al. (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23: 213-21.